XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2

Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details) - Research services combined with an IP license € in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2022 EUR (€)	Sep. 30, 2021 EUR (€)	Sep. 30, 2022 USD ($)	Dec. 31, 2021 EUR (€)
Notes to the consolidated financial statements
Upfront and milestones payments included in contract liabilities	€ 111,817			€ 142,095
Revenue recognized from upfront and milestones payments	40,278	€ 49,878
CRISPR
Notes to the consolidated financial statements
Upfront and milestone payments received or receivable	2,524		$ 3,000
Upfront and milestones payments included in contract liabilities	1,007			1,239
Revenue recognized from upfront and milestones payments	232	232
Boehringer Ingelheim
Notes to the consolidated financial statements
Upfront and milestone payments received or receivable	30,000
Revenue recognized from upfront and milestones payments		9,990
Genmab
Notes to the consolidated financial statements
Upfront and milestone payments received or receivable	8,937		$ 10,000
Upfront and milestones payments included in contract liabilities	4,022			5,362
Revenue recognized from upfront and milestones payments	1,341	1,341
GSK
Notes to the consolidated financial statements
Upfront and milestone payments received or receivable	205,000
Upfront and milestones payments included in contract liabilities	106,788			€ 135,494
Revenue recognized from upfront and milestones payments	38,705	€ 38,315
Minimum | GSK
Notes to the consolidated financial statements
Upfront and milestone payments received or receivable	€ 10,000

X

- Definition

Represents of disclosure of notes to the consolidated financial statements.

+ References

No definition available.

+ Details

Name:	cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems
Namespace Prefix:	cvac_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of upfront payments of the company included in contract liabilities.

+ References

No definition available.

+ Details

Name:	cvac_UpfrontPaymentsIncludedInContractLiabilities
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of upfront payments received or receivable by the company.

+ References

No definition available.

+ Details

Name:	cvac_UpfrontPaymentsReceivedOrReceivable
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 116
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_b&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=cvac_CrisprMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=cvac_GenmabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: